Allergan Keeps Heading Lower. Is It Time to Buy?
Allergan's (NYSE: AGN) stock slid by double digits for the third straight month in October. So after dropping by another 13.5% last month, Allergan's stock has now lost around 30% of its value since the start of August, according to S&P Global Market Intelligence.
The drugmaker's woes stem from two core issues:
Image source: Getty Images.
Source: Fool.com
